Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.79 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.79 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.72 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.71 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.66 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.66 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.66 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.66 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.66 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.66 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.66 |
| ▸ | MGLL | Q99685 | 2/20 | 0.61 |
| ▸ | MMP12 | P39900 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11692787 | 1.00 | MAPT (0.79) | MAPTRXFP1FFAR1HDAC2HDAC1 | |
| SCHEMBL25169928 | 1.00 | MAPT (0.79) | MAPTRXFP1FFAR1HDAC2HDAC1 | |
| SCHEMBL1958621 | 0.98 | FFAR1 (0.75) | MAPTRXFP1FFAR1HDAC2HDAC1 | |
| SCHEMBL1651413 | 0.92 | FFAR1 (0.78) | MAPTRXFP1FFAR1HDAC2HDAC1 | |
| SCHEMBL28199729 | 0.91 | MAPT (0.65) | MAPTRXFP1FFAR1HDAC2HDAC1 | |
| SCHEMBL30536359 | 0.89 | MAPT (0.63) | MAPTRXFP1FFAR1HDAC2HDAC1 | |
| SCHEMBL1008757 | 0.88 | MAPT (1.00) | MAPTRXFP1HDAC2HDAC1HDAC3 | |
| SCHEMBL770290 | 0.88 | MAPT (1.00) | MAPTRXFP1HDAC2HDAC1HDAC3 | |
| SCHEMBL1008045 | 0.88 | MAPT (1.00) | MAPTRXFP1HDAC2HDAC1HDAC3 | |
| SCHEMBL503837 | 0.88 | MAPT (1.00) | MAPTRXFP1HDAC2HDAC1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080187572-A1 | Matrix Metalloproteinase Inhibitors of Tgfb-Induced Subcapsular Cataract Formation | MCMASTER UNIVERSITY (CA) | 2008-08-07 | — | — | US | claimed |
| EP-4526336-A1 | NOVEL RECOMBINANT FIBRINOGEN VARIANTS FOR FIBRIN SEALANTS FOR SURGICAL WOUND CARE | Julius-Maximilians-Universität Würzburg (DE) | 2025-03-26 | — | — | EP | disclosed |
| WO-2023222770-A1 | Novel recombinant fibrinogen variants for fibrin sealants for surgical wound care | JULIUS-MAXIMILIANS-UNIVERSITAET WUERZBURG (DE) | 2023-11-23 | — | — | WO | disclosed |
| US-9353218-B2 | Kit for multifunctional compounds forming crosslinked biomaterials | ANGIOTECH PHARMACEUTICALS, INC. | 2016-05-31 | — | — | US | disclosed |
| US-9326934-B2 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG | 2016-05-03 | — | — | US | disclosed |
| EP-2181704-B1 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INT AG (CH) | 2015-05-06 | — | — | EP | disclosed |
| US-20130289235-A1 | MULTIFUNCTIONAL COMPOUNDS FOR FORMING CROSSLINKED BIOMATERIALS AND METHODS OF PREPARATION AND USE | ANGIOTECH PHARMACEUTICALS, INC. (CA) | 2013-10-31 | — | — | US | disclosed |
| US-8486437-B2 | Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use | ANGIOTECH PHARMACEUTICALS (US), INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8481073-B2 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2013-07-09 | — | — | US | disclosed |
| US-8460708-B2 | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use | ANGIODEVICE INTERNATIONAL GMBH (CH) | 2013-06-11 | — | — | US | disclosed |
| US-20050149157-A1 | Electrical devices and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-07 | — | — | US | disclosed |
| US-20050149158-A1 | Medical implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-07-07 | — | — | US | disclosed |
| US-20050143817-A1 | Medical implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-30 | — | — | US | disclosed |
| US-20050142162-A1 | Soft tissue implants and anti-scarring agents | ANGIOTECH INTERNATIONAL AG (CH) | 2005-06-30 | — | — | US | disclosed |
| US-20040260318-A1 | Anastomotic connector devices | ANGIOTECH INTERNATIONAL AG (CH) | 2004-12-23 | — | — | US | disclosed |
| US-20040225077-A1 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG (CH) | 2004-11-11 | — | — | US | disclosed |
| US-20040219214-A1 | Tissue reactive compounds and compositions and uses thereof | ANGIOTECH INTERNATIONAL AG (CH) | 2004-11-04 | — | — | US | disclosed |
| US-20040199241-A1 | Silk stent grafts | ANGIOTECH INTERNATIONAL AG (CH) | 2004-10-07 | — | — | US | disclosed |
| US-20040192658-A1 | Compositions and methods of using collajolie | ANGIOTECH INTERNATIONAL AG (CH) | 2004-09-30 | — | — | US | disclosed |
| WO-2004060424-A2 | SILK-CONTAINING STENT GRAFT | ANGIOTECH INTERNATIONAL AG (CH) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040219214-A1 | Tissue reactive compounds and compositions and uses thereof | CD44, SELP, EPCAM | MAPT 3086/4885RXFP1 701/4885FFAR1 515/4885 |
| US-20040192658-A1 | Compositions and methods of using collajolie | MMP9, COL2A1, MMP1 | MAPT 2199/4885RXFP1 1454/4885FFAR1 4867/4885 |
| US-20050142162-A1 | Soft tissue implants and anti-scarring agents | MMP1, COL2A1, FN1 | MAPT 4749/4885RXFP1 60/4885FFAR1 2917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.